Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

BACKGROUND: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. METHOD...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Gastric Cancer
Huvudupphovsmän: Hescheler, Daniel A., Plum, Patrick S., Zander, Thomas, Quaas, Alexander, Korenkov, Michael, Gassa, Asmae, Michel, Maximilian, Bruns, Christiane J., Alakus, Hakan
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Singapore 2020
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305081/
https://ncbi.nlm.nih.gov/pubmed/32107691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-020-01045-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk